NCT04373265 2024-02-23
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Corcept Therapeutics
Phase 1 Completed
Corcept Therapeutics
Dana-Farber Cancer Institute
North York General Hospital
Thomas Jefferson University